Esmo
Entity.
- Evidence
- 181 documents · 37 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 14 Apr 2026, last seen 2 Nov 2026
- Measured
- 6% of mentions say something specific about it; the rest only name it
- As of
- 3 Nov 2026
Where this comes from
- European Medical Journal · 2026-11-01 · Targeted ADC Delays Progression in Relapsed Osteosarcoma: ESMO 2026 (opens the source in a new tab)
- BioPharma Dive · 2026-10-30 · This week in charts: ESMO’s winners and losers (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-29 · Podcast: ESMO26: Major readouts from the 2026 congress (opens the source in a new tab)
- The Clinical Trial Vanguard · 2026-10-28 · Hengrui Pharma Presents 64 Studies at ESMO 2026, Record for Chinese Oncology Company (opens the source in a new tab)
- The ASCO Post · 2026-10-28 · Esophageal Cancer Active Surveillance vs Standard Surgery After Neoadjuvant CRT (opens the source in a new tab)
- The ASCO Post · 2026-10-28 · Advanced Biliary Tract Cancer Ivonescimab/Chemotherapy vs Durvalumab/Chemotherapy (opens the source in a new tab)
- Endpoints News · 2026-10-27 · Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO (opens the source in a new tab)
- European Medical Journal · 2026-10-27 · Moderna shares steady after ESMO data leak crash (opens the source in a new tab)
- European Medical Journal · 2026-10-27 · Ivonescimab Improves Survival in Biliary Tract Cancer: ESMO 2026 (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-27 · ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-27 · ESMO26: Intismeran sets new benchmark in adjuvant melanoma (opens the source in a new tab)